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Abstract
Background Methylphenidate (MPH), along with behav-
ioral and psychosocial interventions, is the first-line med-
ication to treat attention-deficit hyperactivity disorder
(ADHD) in Sweden. The dose of MPH for good symptom
control differs between patients. However, studies of MPH
concentration measurement in ADHD treatment are
limited.
Objective To describe blood and oral fluid (OF) concen-
trations of MPH after administration of medication in
patients with well-adjusted MPH treatment for ADHD, and
to identify the most suitable matrix for accurate MPH
concentration during treatment.
Methods Patients were recruited from Child and Adoles-
cent Psychiatry (CAP), General Psychiatry (GP), and the
Department of Dependency (DD). Blood and OF samples
were collected in the morning before MPH administration
as well as 1 and 6 h after administration of the prescribed
morning dose of MPH.
Results Fifty-nine patients aged between 9 and 69 years,
76 % males. The daily dose of MPH varied from 18 to
180 mg, but the median daily dose per body weight was
similar, approximately 1.0 mg/kg body weight. The med-
ian MPH concentration in blood 1 and 6 h after the
morning dose was 5.4 and 9.3 ng/mL, respectively. Highly
variable OF-to-blood ratios for MPH were found at all time
points for all three groups.
Conclusions Weight is a reliable clinical parameter for
optimal dose titration. Otherwise, MPH blood concentra-
tion might be used for individual dose optimization and for
monitoring of the prescribed dose. Relying only on the
outcome in OF cannot be recommended for evaluation of
accurate MPH concentrations for treatment monitoring.
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Key Points
The variability of the administered MPH dose (mg/
kg) between patients was large. However, the
median daily dose of MPH per kg body weight was
similar for all ages, approximately 1.0 mg/kg body
weight. Thus, adults, as they normally weigh more
than children, require higher doses of MPH per day
than children do.
After the morning dose of OROS-MPH, the median
MPH concentration (25th and 75th percentiles) in
blood was 5.4 (3.8–7.7) ng/mL after 1 h and 9.3
(6.6–13) ng/mL after 6 h. Relying only on oral fluid
samples cannot be recommended for evaluation of
accurate MPH concentrations for treatment
monitoring.
Patients with a history of drug abuse did not require
significantly higher doses of MPH to achieve good
ADHD symptom control.
1 Introduction
Pharmacological treatment combined with behavioral and
psychosocial interventions is an important part of a multi-
modal approach to treat attention-deficit hyperactivity disor-
der (ADHD) to enhance the patients’ andparents’ capability to
cope with symptoms and behavioral problems, as well as to
adapt the environment to the child’s specific difficulties [1].
As inmany other countries [2], there is a rise in Sweden in the
use ofADHDmedications: 2.7 %of children (5–19 years old)
and 0.9 % of adults (20–65 years old) purchased a prescribed
ADHD medication in 2015 [3]. Compared to 2006, this cor-
responds to a 4.4-fold increase in children and a 6.3-fold
increase in adults. The first-line drug treatment for ADHD in
Sweden ismethylphenidate (MPH) [3, 4, 5]: 70.1 %ofADHD
prescriptions for children and 66.2 % for adults in 2015.Other
prescribed drugs were atomoxetine 15.2 % for children and
10.8 % for adults as well as lisdexamphetamine 14.3 % for
children and 18.2 % for adults.
MPH is rapidly and extensively metabolized in liver and
other tissues by non-microsomal hydrolytic esterases, car-
boxylesterases (CES) [6–8] to its major and essentially inac-
tive metabolite ritalinic acid (RA) [9]. The half-life of MPH
ranges from 2 to 3 h both in adults and in children [10, 11].
In clinical experience, the optimal dose for good
symptom control varies between patients. Clinical guide-
lines recommend a stepwise titration with careful moni-
toring of both beneficial and side effects [12]. Since MPH
is a controlled drug with potential risk for abuse,
prescription rates are monitored by Swedish authorities
[13]. To this day, data on use of MPH concentration for
therapy control in ADHD treatment are limited. The
majority of the studies on pharmacokinetics (PK) of MPH
concern healthy volunteers, and more infrequently, chil-
dren [14–18]. One of the few studies concerning clinical
use of MPH concentration examines medication adherence
with the use of oral fluid (OF) as sampling matrix [19]. The
few studies reporting blood concentrations of MPH have
methodological limitations, such as small sample size and
not rarely, vague diagnostic routines. It would be desirable
to establish a correlation between MPH concentrations and
good symptom control that does not rely only on subjective
reports from patients (and in the case of children from
parents and teachers) to improve treatment efficacy. Also,
treatment of former drug abusers is a topic worth
investigating.
The aim of this naturalistic study was to determine MPH
concentrations (in blood and OF) in patients with well-
adjusted MPH treatment for ADHD. Patients include:
children, adults with no history of drug abuse, and adults
with former drug and/or alcohol abuse. An additional aim
was to determine whether OF can be used to predict blood
concentrations and thus be useful for monitoring of MPH
treatment.
2 Patients and Methods
2.1 Participants
Patients were recruited from outpatient clinics in Child and
Adolescent Psychiatry (CAP), General Psychiatry (GP),
and the Department of Dependency (DD). Participants
were informed about the study by their clinical doctor and
asked if they wished to participate. Written informed
consent was collected from all patients (for the children
also from their parents). The participants received no
financial compensation. Participation was voluntary and in
no way affected MPH treatment.
Inclusion criteria were: DSM-IV ADHD diagnosis ver-
ified by an experienced clinician at CAP, GP or DD,
chronic treatment with a prolonged release formulation of
MPH, and a clinically titrated optimal dose considered to
provide good symptom control, i.e., a reduction of ADHD
symptoms to level 2 on the 7-grade Clinical Global
Impression–Severity scale. The dosing was optimized by
careful clinical examination and in most cases monitored
with the help of both questionnaires and computer-based
assessment of core symptoms of ADHD: QbTest [20] or
test of variables of attention (TOVA) [21] performed
approximately 1–3 h after morning intake of MPH. The
DD patients had been substance abuse free C3 months (as
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tested with urinary samples), however, moderate alcohol
use was accepted. Patients with comorbid autism spectrum
disorder and/or moderate mental retardation were exclu-
ded. Also, poor dental status was an exclusion criterion (to
avoid blood contamination in OF samples). Other psychi-
atric comorbidities, such as anxiety disorder and affective
illness, were accepted.
2.2 Methylphenidate Sampling
On the appointed day, participants were instructed not to
take their morning dose of MPH at home. If they normally
were taking more than a morning dose of MPH, they were
instructed not to take that dose on the previous day as well
as during the study day. Samples were collected at the
Department of Psychiatry at Oskarshamn Hospital, the
Department of Psychiatry at Va¨stervik Hospital, the
Department of Drug Dependence at the University Hospital
Linko¨ping, the Department of Psychiatry at the University
Hospital Linko¨ping, the Department of Psychiatry at
Ryhov County Hospital Jo¨nko¨ping, and for the children, at
the Clinical Pharmacological Department at the University
Hospital Linko¨ping. Blood and OF were collected in the
morning upon arrival as trough concentration (time 0). The
participants subsequently took their prescribed morning
dose of MPH, and two further samples were taken after 1
(time 1) and 6 (time 6) hours, since the prolonged release
formulation of MPH has expected peak blood concentra-
tions approximately 1–2 and 5–7 h post-dose [22]. A
specifically designed request form was used to acquire
relevant clinical data on the patient at the time of sampling.
Blood samples were collected in Venosafe plastic
tubes containing Na-Fluoride/Na-Heparin. For OF collec-
tion, Salivetteplastic tubes containing a cotton wool swab
were used. All samples aliquoted and stored at -20 C
before transportation to the laboratory for long time storage
at -70 C until drug analysis of MPH and RA metabolite
were performed. Drug-free blood collected from healthy
volunteers was purchased from the local University
Hospital (Linko¨ping, Sweden). Drug-free OF was obtained
from laboratory staff volunteers.
2.3 Analysis
Blood and OF samples were analyzed by liquid chro-
matography tandem-mass spectrometry (ESI-LC–MS/MS)
according to a previously described procedure [23]. The
instrumentation consisted of an Acquity Ultra High Per-
formance Liquid Chromatographic (UHPLC) system
(Waters, Milford, MA, USA) and an API 4000 tandem
quadrupole instrument equipped with an electrospray
interface operating in positive ion mode (Applied Biosys-
tem/MSD Sciex, Stockholm, Sweden). Chromatography
was carried out on a Synergi Polar-RP 50 9 2 mm i.e.,
2.5 lm column (Phenomenex, Torrance, CA, USA). Data
were recorded by scheduled multiple reaction monitoring
(MRM), including the two most intense transitions for
MPH, RA, and the internal standards MPH-D9 and RA-
D10. Samples (100 ll blood or OF) were prepared by
protein precipitation before analysis. The range of quan-
tifications was 0.20–30 ng/mL for MPH and 10–1500 ng/
mL for RA in blood as well as 1–500 ng/mL for MPH and
0.25–125 ng/mL for RA in OF. Low and high concentra-
tion control samples were analyzed in each run. For MPH,
the between-day precision (CV) was equal to or better than
10 % in both blood and OF, while the precision for RA was
equal to or better than 15 %. The accuracy was within
90–110 % for control concentrations in blood and OF.
2.4 Statistical Analyses
Median values, the 25th and 75th percentiles, mean values,
and range were computed. Besides descriptive statistics,
covariations between variables were analyzed using the
Spearman rank correlation coefficient (rs). For comparisons
between two groups, the Mann–Whitney U test was used
(unevenly distributed data). For multiple comparisons, the
Kruskal–Wallis test was performed. Sign test and Friedman
ANOVA were used for comparing dependent variables.
Statistical significance was predefined as p\ 0.05 (2-
tailed). The coefficient of variation (CV) was used to
estimate inter-individual variability. Data points below the
limit of quantification (LOQ) were excluded from the
calculations. The computer software STATISTICA 10
(StatSoft, Inc., USA) was used for the statistical
computations.
Dose normalization: to enable the comparison among
patients who had taken different doses of MPH, the blood
concentrations of MPH and the RA metabolite were nor-
malized against the ratio of morning dose to body weight.
Proportional dose–concentration linearity was assumed.
The concentration-to-dose per weight [C/(D/weight)]
acquired in this way approximates the drug concentration
in ng/mL per mg of administered drug and kg body weight
[(ng/mL)/(mg/kg)].
3 Results
A total of 59 patients were enrolled into the study: 38
adults (22 patients from GP and 16 patients from DD)
and 21 children from CAP. For demographics and
baseline characteristics, see Tables 1 and 2. The majority
of subjects were male (76 %), almost all had ADHD-
combined type (97 %) and had normal or above average
intelligence (95 %). Ninety-five percent of the adults had
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received no special help in school in contrast to the great
majority of the children (86 %). The mean MPH treat-
ment length was almost 2 years, and the mean time on
the present dose of MPH was just over 1 year. Among
the adults, 47 % had another previous/concurrent psy-
chiatric diagnosis while this was the case for only 19 %
of the children.
All patients from DD had a history of previous mixed
drug abuse. The ‘‘preferred drug of abuse’’ was alcohol in
44 % of the cases and intravenous drugs (mostly
amphetamines) in 56 %. Among patients from GP, 14 %
had a history of previous alcohol abuse. No child had any
reported drug abuse.
The majority of the adults had other concomitant phar-
macological treatment (76 %) while this was the case in
only a minority of the children (14 %). Among the adults,
50 % was taking at least one central nervous system
(CNS)-active drug [categorized as ‘‘N’’ according to the
Anatomical Therapeutic Chemical (ATC) Classification
system]. The most common co-medications were antide-
pressants (N06A, n = 15 patients, e.g. sertraline or
citalopram) as well as anxiolytics, sedatives, and hypnotic
drugs (N05B, n = 7 patients, e.g., diazepam or oxazepam;
N05C, n = 7 patients, e.g., propiomazine or melatonine).
The most frequent ‘‘somatic’’ drugs (categorized according
to the other ATC groups, beyond ‘‘N’’) were drugs for the
Table 1 Demographic and
baseline characteristics from the
medical record
GP DD CAP All patients
Number (n) of patients 22 16 21 59
Gender, n
Male 14 11 20 45
Female 8 5 1 14
Age (y), median (range)
All 39 (18–67) 46 (21–69) 12 (9–17) 33 (9–69)
Male 38 (18–67) 48 (21–69) 12 (9–17) 24 (9–69)
Female 42 (19–52) 35 (27–58) 10 39 (10–58)
ADHD type, n
ADD 0 1 1 2
ADHD-combined 22 15 20 57
Intelligence Quotient estimate, n
Above average intelligence 0 2 1 3
Normal or average intelligence 22 14 17 53
Lower normal range 0 0 3 3
School education, n
Regular classes without support person 22 14 3 39
Regular classes with support person 0 1 14 15
Special school 0 1 4 5
Treatment history, mean (range)
Age (y) first entered treatment 39 (18–65) 43 (21–67) 10 (6–16) 30 (6–67)
Time (m) for treatment 15 (4–44) 21 (4–76) 33 (4–69) 23 (4–76)
Time (m) for treatment with present dose 14 (3–44) 13 (1–38) 15 (2–35) 14 (1–44)
Previous/concurrent psychiatric diagnoses, n
None 15 5 17 37
Language disorder 0 0 3 3
Pervasive developmental disorder 1 0 1 2
Anxiety/depression 6 11 0 17
Previous drug abuse (‘‘preferred drug’’), n
None 19 0 21 40
Amphetamines 0 8 0 8
Alcohol 3 7 0 10
Heroin 0 1 0 1
y years, m months, GP General Psychiatry, DD Department of Dependency, CAP Child and Adolescent
Psychiatry, ADHD attention-deficit hyperactivity disorder, ADD attention-deficit disorder
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alimentary tract and metabolism (‘‘A’’, n = 10 patients,
e.g., omeprazole or metphormine) as well as for the car-
diovascular system (‘‘C’’, n = 8 patients, e.g. metoprolol
or enalapril). The majority of adults (53 %) had at least two
drugs beyond MPH treatment. No patient was being treated
with neuroleptics.
None of the children were smokers, while 68 % of the
adults smoked daily. Daily caffeine consumption (coffee or
soft drinks) was reported by 89 % of adults and 33 % of
children. The majority of the adults used alcohol, 26 % had
a large consumption, i.e., more than one glass of wine for
women or two glasses of wine for men per day.
The daily dose of MPH varied from 18 to 180 mg.
Thirty-five patients were prescribed MPH once a day in the
morning, while 24 patients had more than one daily dose.
The median daily dose was significantly lower (p\ 0.001)
in children than in adults, 50 and 81 mg, respectively,
while the median daily dose per kg body weight was the
same (approximately 1.0 mg/kg) in all three groups
(p = 0.89).
Table 2 Baseline characteristics from the request forms
GP DD CAP All patients
Current daily dose (mg/day), median (range)
All 72 (18–180) 90 (36–180) 50 (27–74) 72 (18–180)
Male 81 (18–180) 90 (36–180) 50 (27–74) 54 (18–180)
Female 72 (27–126) 90 (72–126) 36 72 (27–126)
Dose regimen, n
Once a day 9 10 16 35
Twice daily 10 6 4 20
Three times a day 3 0 1 4
Weight (kg), median (range)
All 82 (57–122) 84 (64–138) 35 (30–90) 72 (30–138)
Daily dose to weight (mg/kg), median (range)
All 1.1 (0.18–2.2) 1.0 (0.43–1.9) 1.0 (0.60–2.2) 1.0 (0.18–2.2)
Male 1.1 (0.18–2.0) 1.0 (0.43–1.8) 1.0 (0.60–2.2) 1.0 (0.18–2.2)
Female 1.1 (0.41–2.2) 1.1 (0.86–1.9) 1.1 1.1 (0.41–2.2)
Concomitant medication, n
MPH onlya 6 3 18 27
MPH ? CNSb 12 7 3 22
MPH ? 1 drugc 7 2 2 11
MPH ? C2 drugsc 9 11 1 21
Other medication, n
Herbal medicine 4 6 1 11
Temporally/local treatment 9 8 6 23
Nicotine, n
Yes, daily 13 13 0 26
[10 mg 9 6 – 15
Caffeine, n
Yes, daily 19 15 7 41
[0.5 g 6 9 0 15
Present alcohol consumption, n
Yes 16 9 0 25
Daily 4 3 – 7
Large consumption 6 4 – 10
GP General Psychiatry, DD Department of Dependency, CAP Child and Adolescent Psychiatry, MPH methylphenidate, RA ritalinic acid
a MPH monotherapy
b Co-medication with CNS-active drugs
c Co-medication with CNS-active drug or ‘‘somatic’’ drug
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MPH blood concentration at time 0 was very low
(Table 3). Eight patients had concentrations below the
LOQ (three patients in GP, three in DD, and two in CAP).
One adult patient with MPH blood concentration at time 0
below the LOQ, reported on the study day that he could not
remember if he took the previous morning dose of 72 mg
MPH. One adult treated with 60 mg twice a day had a
concentration of 16 ng/mL. RA blood concentrations were
quantifiable in all samples and were higher than MPH
blood concentrations (30- to 3000-fold). No correlation
(rs = 0.16, p = 0.23) could be found between the dose
taken the day before the study day and the trough blood
concentration of MPH.
On the study day, 50 patients took osmotic release oral
system (OROS)-MPH (Concerta). The remaining nine
patients took extended release MPH (Ritalin or
Medikinet). Five patients took an immediate release for-
mulation of MPH (Ritalin or Medikinet) as add-on to
extended release formulations.
3.1 OROS-Methylphenidate Patients
To reduce data variability due to differences in drug for-
mulation, only the patients that took OROS-MPH (n = 50)
were considered for further analysis. The blood concen-
trations of MPH and RA of these patients are shown in
Table 3. Six patients had concentrations below the LOQ at
time 0 (three patients in GP and three in DD). The range of
concentration at time 0 was from not detected to 4.1 ng/
mL. Blood concentrations of MPH at time 1 and at time 6
rose as expected, as shown in Fig. 1. The median MPH
blood concentration increased approximately ninefold from
Table 3 Methylphenidate
analysis in blood
GP DD CAP All patients
All participants
Number (n) of patients 22 16 21 59
Male:Female (n) 14:8 11:5 20:1 45:14
Age (y) 39 (18–67) 46 (21–69) 12 (9–17) 33 (9–69)
Trough sampling timesa (h)
time 0 24.2 (19.9–27.8) 25.3 (18.7–27.9) 24.5 (14.9–25.9) 24.9 (14.9–27.9)
Blood concentration at time 0 (trough concentration)
MPH ng/ml 0.59 (\0.20c–16) 0.90 (\0.20c–4.1) 0.70 (\0.20b–1.9) 0.63 (\0.20e–16)
RA ng/ml 177 (14–671) 168 (15–290) 95 (14–269) 131 (14–671)
RA/MPH 289 (42–952) 212 (38–911) 157 (28–434) 202 (28–952)
Patients with the osmotic release oral system (OROS)-MPH
Number (n) of patients 18 16 16 50
Male:Female (n) 11:7 11:5 15:1 37:13
Age (y) 39 (18–67) 46 (21–69) 12 (9–17) 34 (9–69)
Blood concentration at time 0 (trough concentration)
MPH ng/ml 0.49 (\0.20c–2.3) 0.90 (\0.20c–4.1) 0.70 (0.35–1.9) 0.65 (\0.20d–4.1)
RA ng/ml 118 (14–599) 168 (15–290) 94 (14–269) 126 (14–599)
RA/MPH 289 (97–953) 213 (38–911) 135 (28–267) 189 (28–953)
Morning dose (mg) 54 (18–126) 72 (36–144) 36 (27–54) 54 (18–144)
Blood concentration at time 1 (1 h after the morning dose)
MPH ng/ml 5.2 (1.1–16) 7.1 (3.3–18) 5.6 (0.30–13) 5.8 (0.30–18)
RA ng/ml 229 (71–852) 343 (266–728) 198 (52–512) 294 (52–852)
RA/MPH 51 (26–120) 58 (16–104) 37 (22–327) 47 (16–327)
Blood concentration at time 6 (6 h after the morning dose)
MPH ng/ml 7.6 (2.2–25) 10 (2.9–20) 13 (5.7–22) 10 (2.2–25)
RA ng/ml 425 (104–1090) 491 (293–1100) 396 (213–511) 427 (104–1100)
RA/MPH 52 (26–102) 54 (20–119) 34 (19–66) 44 (19–119)
Data are presented as median (range) unless specified otherwise
GP General Psychiatry, DD Department of Dependency, CAP Child and Adolescent Psychiatry, MPH
methylphenidate, RA ritalinic acid
a The time elapsed between the last administration and the sample collection
Data points below the LOQ were excluded from the calculations: number of patients = b2, c3, d6, e8
300 M. D. Cherma´ et al.
time 0 to time 1 and 1.5-fold from time 1 to time 6. The
distribution of MPH blood concentrations at time 1 and at
time 6 in these patients is presented in Fig. 2.
Only in the adults, significant (p\ 0.001) correlations
were found between MPH blood concentration and morn-
ing dose (time 1, rs = 0.63 and time 6, rs = 0.64) as well
as between MPH blood concentration and morning dose
per body weight (time 1, rs = 0.66 and time 6, rs = 0.69).
The correlation between blood concentration of MPH and
RA was rs = 0.63 at time 1 and rs = 0.69 at time 6.
No significant differences were found between patients
from GP (n = 18) and DD (n = 16) in daily dose
(p = 0.15), body weight (p = 0.41), daily dose per body
weight (p = 0.57), MPH blood concentrations (time 1,
p = 0.06; time 6, p = 0.38) or RA blood concentrations
(time 1, p = 0.05; time 6, p = 0.26). Consistently, no
significant differences in [C/(D/weight)] for MPH and RA
were found between patients from GP and DD at any time
point.
Among adults, no significant differences were found
between men (n = 22) and women (n = 12) in daily dose
(p = 0.70), daily dose per body weight (p = 0.40), MPH
blood concentrations (time 1, p = 0.24; time 6, p = 0.23) or
RA blood concentrations (time 1, p = 0.80; time 6,
p = 0.15). Nonetheless, a significant difference in body
weight was found (p\ 0.001). However, no significant dif-
ferences were found between adult men and women in [C/(D/
weight)] for MPH and RA at any time point. Among children,
the number of girls was too low to be analyzed separately.
Between adults (n = 34) and children (n = 16), sig-
nificant differences were found in daily dose (p\ 0.001)
and body weight (p\ 0.001) but not in the dose adjusted
for body weight (p = 1.0). Adults had higher median daily
dose and higher median weight than children (72 vs 36 mg
and 82 vs 37 kg, respectively). The prescribed median
daily dose MPH was 1.0 mg/kg for adults and children. No
significant differences were found between adults and
children in MPH blood concentrations at any time point
(time 1, p = 0.67; time 6, p = 0.11) or in [C/(D/weight)]
for MPH (time 1, p = 0.09; time 6, p = 0.52). The RA
blood concentrations were lower in children than in adults,
approximately 40 % lower at time 1 (p\ 0.05) and 12 %
lower at time 6 (p = 0.09). Consistently, significant dif-
ferences were shown in [C/(D/weight)] for RA between
adults and children at all time points (p\ 0.05). Children
had lower [C/(D/weight)] of RA blood concentrations than
adults. As a consequence, the metabolic ratio (RA/MPH)
was significantly lower in children than in adults at all time
points (time 1, p\ 0.05; time 6, p\ 0.001). In all, an
inter-individual variability was observed for [C/(D/
weight)] of both MPH blood concentrations (time 1,
CV = 55 %; time 6, CV = 39 %) and RA blood concen-
trations (time 1, CV = 44 %; time 6, CV = 29 %).
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Fig. 1 Concentration–time profile of methylphenidate (MPH) blood
concentrations in 50 patients before and after the morning dose (1 and
6 h) of the osmotic release oral system (OROS)-MPH
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Fig. 2 Frequency distribution of blood methylphenidate (MPH)
concentrations in 50 patients 1 and 6 h after the morning dose of
the osmotic release oral system (OROS)-MPH
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No significant correlation was found between morning
dose and RA/MPH ratio, neither at time 1 (rs = 0.22,
p = 0.12) nor at time 6 (rs = 0.25, p = 0.05). Similarly,
correlation fails to be significant for morning dose per body
weight and RA/MPH ratio. As shown in Table 3, the RA/
MPH ratio did not differ at time 1 and at time 6 in each
group (GP, p = 1,0; DD, p = 0.45; CAP, p = 0.61). On
the other hand, the RA/MPH ratio at time 0 was signifi-
cantly higher (p\ 0.001) than at time 1 and at time 6 in all
groups. The correlations between morning doses and
metabolic ratio were rs = 0.22 at time 1 (p = 0.13) and
rs = 0.28 at time 6 (p = 0.05).
The possible interaction of one particular drug on the
blood concentration of MPH could not be shown because
of the very few number of reports for a drug. However, we
did not find any differences between the different ATC
groups ([5 patients/group) in daily dose per body weight
(p = 0.14) or dose normalization for MPH (time 1,
p = 0.70; time 6, p = 0.65).
Among children, the number of caffeine consumers was
too low to be analyzed separately. In the adults, the median
daily dose per body weight was 1.1 mg/kg in high ([0.5 g)
daily caffeine consumers (n = 14) and 0.88 mg/kg in
nonuser or intermittent users (n = 20), p = 0.05. No sig-
nificant differences were found in dose normalization for
MPH between these groups. Further, no significant differ-
ences were found in daily dose per body weight or dose
normalization for MPH neither between high ([10 mg)
daily nicotine consumers (n = 13) and nonuser-low nico-
tine consumers (n = 20) nor between daily alcohol con-
sumers (n = 9) and not daily alcohol consumers (n = 25).
A stratification procedure was applied to increase PK
data reliability. When dose–concentration correlation was
calculated for dose concentrations with more than five
patients per dose (Table 4), no relationship was found at
time 1 and (rs = 0.08, p = 0.64) and at time 6 (rs = -
0.05, p = 0.76), neither for adults nor children. No sig-
nificant differences were found between the doses in this
subgroup for MPH blood concentration at time 1
(p = 0.63) and at time 6 (p = 0.91). The median MPH
blood concentration (25th and 75th percentiles) was 5.4
(3.8–7.7) ng/mL at time 1 and 9.3 (6.6–13) ng/mL at time
6. The median RA blood concentration was higher at dose
72 mg intake, but it is worth pointing out that all patients
with 72 mg were adults, and 62 % of patients with 36 mg
were children. The RA/MPH ratio was also higher but this
difference was not significant.
3.2 Oral Fluid
Oral fluid (OF) samples were taken in parallel to the blood
samples (Table 5). MPH in OF was found highly instable,
and the OF had to be centrifuged immediately and frozen in
-70 C until analysis to prevent degradation. Many
patients (not only the children) also had difficulties pro-
viding enough OF, and in several instances, the OF was
contaminated with blood from gingival bleeding. In every
OF sample, MPH concentrations were higher (median
about fourfold) than in blood. Conversely, RA concentra-
tion in OF was about 25-fold lower than in blood.
Intra-individual patient comparison showed significant
(p\ 0.001) correlations between MPH concentrations in
OF and in blood at all time points (time 0, rs = 0.53; time
1, rs = 0.69; time 6, rs = 0.54) as well as between RA
concentrations in OF and in blood (time 0, rs = 0.68; time
1, rs = 0.77; time 6, rs = 0.63). However, a high inter-
individual patient variability of the OF-to-blood ratio of
MPH (MPHS/MPH) was found at time 0 (CV 130 %), at
time 1 (CV 131 %), and at time 6 (CV 100 %) as well as of
the OF-to-blood ratio of RA (RAS/RA) at all time points
Table 4 Methylphenidate
blood concentrations ([5
patients per dose of OROS-
MPH)
Morning dose 36 mg 54 mg 72 mg
Number (n) of patients 13 14 9
Age (y) 12 (9–69) 18 (11–67) 45 (21–54)
Male:Female, n 10:3 12:2 5:4
Blood concentration at time 1 (1 h after the morning dose)
MPH ng/ml 4.8 (0.30–13) 5.8 (2.8–18) 5.5 (2.7–10)
RA ng/ml 184 (71–512) 228 (166–545) 343 (224–594)
RA/MPH 40 (22–326) 46 (16–88) 70 (38–120)
Blood concentration at time 6 (6 h after the morning dose)
MPH ng/ml 11 (3.0–20) 9.2 (5.5–22) 9.3 (2.9–15)
RA ng/ml 352 (193–470) 402 (303–659) 475 (307–814)
RA/MPH 36 (19–101) 43 (20–92) 64 (28–119)
Data are presented as median (range)
MPH methylphenidate, RA ritalinic acid, OROS-MPH osmotic release oral system (OROS)-MPH
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(time 0, CV 122 %; time 1, CV 89 %; time 6, CV 69 %).
Also, in the patients that took OROS-MPH, no significant
correlations were found between morning dose and MPH
concentrations in OF at time 1 (rs = 0.18, p = 0.21) and at
time 6 (rs = 0.27, p = 0.06).
The MPHS/MPH ratio did not vary at the different time
points (p = 0.29). On the other hand, the RAS/RA ratio
varied between the time points (p\ 0.001). No significant
differences were shown between the three patient groups
for OF-to-blood ratio of MPH and RA.
4 Discussion
This naturalistic study presents a detailed description of
MPH and RA blood concentrations in child and adult
patients with well-adjusted MPH treatment for ADHD.
Good clinical effect on symptoms was achieved by careful
dose titration performed with the help of questionnaires
and computer-based assessment. The findings show that the
median daily dose of MPH per kg body weight was similar
between all three patient groups (approximately 1.0 mg/
kg). This is well in accordance with the research literature
that suggests titrating MPH to 1.0 mg/kg for the best
behavioral response in children [24]. Thus, adults, as they
normally weigh more than children, require a higher daily
dose of MPH per day than children do. This study supports
the advice from clinical guidelines to adjust the MPH dose
through stepwise titration to at least 1.0 mg MPH per kg
body weight and possibly up to approximately 1.2–2.2 mg/
kg, according to our data. This is well in accordance with
the findings from the MTA study in which carefully
monitored medication clearly outplaced less rigorous
practice [25].
The need in clinical routine for a carefully titrated per-
sonalized dose is reflected in the large variability between
patients of the administered MPH dose (18–180 mg/day).
Despite this, in the cohort of patients which took OROS-
MPH in the morning of the study day, the [C/(D/weight)]
of MPH in blood did not differ between the three groups
studied. The concentrations of MPH in blood were after
1 h, 5.4 (3.8–7.7) ng/mL and after 6 h, 9.3 (6.6–13) ng/mL.
These concentrations are in accordance with other studies
that reported therapeutic concentrations in blood [26, 27].
Considering this, we would suggest that blood concentra-
tions of MPH might be used for dose optimization to
ensure optimal clinical benefit of MPH treatment. This may
be supported by positron emission tomography (PET)
studies, which found a correlation between blood concen-
tration of MPH and dopamine transporter (DAT) occu-
pancy, the main target of MPH in the brain [28–30]. The
clinical use of blood concentrations might be also used to
monitoring the prescribed dose, e.g., in patients requiring
higher than approved dosing of MPH, since we find an
association between morning dose and MPH blood con-
centrations in adults. A controlled setting might also con-
tribute to the adherence of MPH treatment.
In this study, patients with a history of drug abuse did
not require significantly higher doses of MPH to receive
good ADHD symptom control. This is a good argument in
reply to clinicians who argue that MPH treatment of former
drug abusers is nothing more than substitution treatment
for their drug abuse [31]. We show that the effective MPH
doses for former drug abuser patients from DD were not
higher than for patients in GP.
The metabolic ratio (RA/MPH) was similar for adults
but significantly lower in children. Metabolic ratio is
considered as a measure of metabolic clearance. The
Table 5 Methylphenidate
analysis in oral fluid
GP DD CAP All patients
Number (n) of patients 22 16 21 59
Concentration at time 0 (trough concentration)
MPHS/MPH 5.4 (1.8–54) 3.1 (1.1–11) 4.5 (1.6–8.2) 4.5 (1.1–54)
RAS/RA 0.04 (0.02–0.35) 0.03 (0.01–0.08) 0.04 (0.02–0.43) 0.04 (0.01–0.43)
Concentration at time 1 (1 h after the morning dose)
MPHS/MPH 3.9 (1.5–54) 4.3 (1.5–18) 3.6 (1.6–12) 3.8 (1.5–54)
RAS/RA 0.03 (0.02–0.25) 0.02 (0.01–0.06) 0.03 (0.01–0.06) 0.03 (0.01–0.25)
Concentration at time 6 (6 h after the morning dose)
MPHS/MPH 4.3 (1.7–29) 4.7 (2.0–29) 2.8 (1.1–7.6) 3.8 (1.1–29)
RAS/RA 0.05 (0.02–0.21) 0.04 (0.02–0.09) 0.03 (0.02–0.05) 0.04 (0.02–0.21)
Data are presented as median (range) unless specified otherwise
MPHS methylphenidate concentration in oral fluid, RAS ritalinic acid concentration in oral fluid, MPH
methylphenidate concentration in blood, RA ritalinic acid concentration in blood, GP General Psychiatry,
DD Department of Dependency, CAP Child and Adolescent Psychiatry
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different patterns between adults and children may possibly
be due to maturation effects of carboxylesterase with low
levels of CES expression during early developmental
stages [16, 31, 32]. However, clearance of MPH and RA
via other pathways and elimination of the metabolite will
also affect the metabolic ratio. The study showed a time-
dependent increase of the RA/MPH ratio after the highest
MPH blood concentration at time 6 to the next dose at time
0, possibly due to the slower elimination of RA than MPH
[33].
OROS-MPH was developed with the aim to without
compromise of effectiveness not cause acute pharmaco-
dynamic tolerance. The delivery system was designed to
provide successively increasing blood concentrations with
a 12-h duration across the day [34]. We confirmed such
delayed increase since we showed MPH blood concentra-
tions increased 1 and 6 h after a morning dose. However,
some patients claim that the effect of their medication
fades away much sooner than the expected 10–12 h. Some
adult patients took OROS-MPH more than once a day
(41 %). A study in prison inmates with ADHD showed that
OROS-MPH intake in the morning and at noon maintained
symptoms relief throughout the day [35]. It is conceivable
that these patients react to that their blood concentration no
longer increase after a few hours and therefore need a
booster dose since the clinical effectiveness could be more
related to the ascending profile than the flat profile [29, 36].
At time 0 (trough concentration), the blood concentrations
of MPH were expected to not be detected (below the LOQ)
due to the short half-life of the MPH and the overnight
washout period. However, it is noteworthy that MPH blood
concentrations in 86 % of patients in our study remained
detectable until the following morning dose. In fact, med-
ian trough blood concentrations of MPH were 6 % of the
median highest blood concentrations of MPH. A relatively
constant MPH blood concentration could be a possible risk
factor for developing pharmacodynamic tolerance [34, 36].
Many persons with ADHD consume large amount of
dopamine active agents, such as nicotine in cigarettes and
caffeine in coffee and soft drinks, as well as alcohol. In this
study, all adults reported consumption of at least one dopa-
mine active agent. About one-third of the children reported
consumption of caffeine. Some studies show that caffeine
may induce pharmacodynamic tolerance [37, 38]. Further-
more, it is known that the transesterification of MPH after
coadministration with ethanol form ethylphenidate, a
selective dopaminergic agonist [39, 40]. Though, in our data,
no differences were found between patients regarding high
consumption or not of caffeine, nicotine or alcohol.
As expected, the optimal oral MPH dose per day dif-
fered between patients. This variability might be due to
differences in absorption of MPH that has been shown to
vary between 10 and 52 % [41], as well as due to
differences in metabolism [42, 43]. Since polymorphisms
for the principal enzyme responsible for the de-esterifica-
tion of MPH to RA (CES1) have a low frequency, it is a
less plausible cause for this variability. But, CES1 poly-
morphisms might be important for individual carriers that
may require lower doses of MPH for symptom reduction or
as regards toxicities. Further, polymorphisms in DAT and
dopamine D4 receptor genes could affect the clinical effect
of a given dose of MPH, but previous pharmacogenetics
studies are limited [44].
Finally, we investigated whether OF could replace blood
as a matrix for analysis of MPH concentration for the
monitoring of MPH treatment, since OF as sampling matrix
could be an attractive alternative for a more convenient
sampling without the need for venepuncture. MPH con-
centrations were much higher in OF than in blood, proba-
bly due to active secretion similar to other amphetamine-
like compounds [45, 46]. Conversely, RA concentrations in
OF showed an opposite trend. RA does not readily pass
into OF, and thus, measured concentrations were low.
Although a correlation was found between MPH concen-
tration in OF and in blood within the same patient, in
agreement with the literature [45], there was very large
variation of the MPHS/MPH between patients. We would,
thus, not advocate OF analysis of MPH as a safe method
for monitoring of MPH treatment. MPH concentration in
OF may be used for follow-up of the treatment over time in
a single patient provided that the MPHS/MPH ratio has
been determined at start. However, the stability of MPH in
OF samples must be ensured. It is possible that the same
methodological problems in OF analysis of MPH that we
encountered could explain the puzzling findings from the
MTA study of discrepancies between parents’ reports of
good compliance with medication and MPH concentrations
not detectable in OF analysis [19].
This study has the advantage of a naturalistic study, i.e.,
a reflection ‘‘real life’’ circumstances. There are some
limitations but also some obvious strengths. The study
displays the panorama in the everyday clinical setting with
patients with well-adjusted doses to provide clinical good
symptom control. Thus, this study reports blood concen-
tration ranges of MPH and RA in normal clinical settings,
analyzing a heterogenic population never found in pre-
registration clinical trials. MPH blood and OF analyses
were completed in the same laboratory with a well-devel-
oped and stable method for quantitative analysis that is
proven to cover clinically relevant concentrations of MPH
and RA. The small size of the investigated group neither
enables comparisons between sexes nor between different
co-medications or consumption of dopamine active agents
between the patients. Together with the limited geograph-
ical distribution of the recruited subjects, this limitation
makes the study prone to a type II error, and thus reduces
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the soundness of dose comparisons across groups. Also,
dose allocation was not randomized, so, confounding fac-
tors must be considered. Lastly, the presence of ethylphe-
nidate and its possible significance was not investigated.
5 Conclusions
Adjusting the prescribed MPH dose to approximately
1.0 mg/kg body weight via stepwise dose titration is a
reliable clinical approach, valid for both children and
adults even with a history of drug abuse. MPH blood
concentrations in our study were within the range of con-
centrations reported to be therapeutic for ADHD. Mea-
suring blood concentrations of MPH could be used for
individual dose optimization and for monitoring of the
prescribed dose, e.g., if patients are craving for high doses
of MPH. Relying only on the outcome in OF cannot be
recommended for evaluation of accurate MPH concentra-
tions for treatment monitoring.
More studies are necessary to evaluate possible differ-
ences in PK of MPH between the sexes and among con-
sumers of dopamine active agents in this population. It
would be desirable to confirm the blood concentration
ranges of MPH and RA reported in this study to ensure
optimal clinical benefit of MPH treatment as well as the
possible role of the metabolite ethylphenidate.
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